ConfirmMDx, a new epigenetic assay to prevent repeat biopsies

1 / 1
Share this content:

ConfirmMDx, an epigenetic assay developed by MDxHealth, uses an epigenetic field effect ("halo") to determine the risk of cancerization at a DNA level. The innovative test can help to single out men without a risk of prostate cancer from undergoing unnecessary biopsies as well as identify patients who need treatment.

Click here to watch E. David Crawford, MD, talk about his experience with MDx.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters